Biogen (BIIB)
(Delayed Data from NSDQ)
$225.43 USD
-6.56 (-2.83%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $225.96 +0.53 (0.24%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 421 - 440 ( 804 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Neurology Prescription Sales Tracker - Week Ending 8/21/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
This report covers the Multiple Sclerosis Drug Market
Provider: Standpoint Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Whoomp! There It Is! Mylan Launches Tecfidera Generic
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
FDA Approves Generic Tecfidera From Mylan - Now What?
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Considerations for Ongoing Tecfidera Litigation and ?514 Patent
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
BIIB Makes Next Step Towards Aducanumab Review - Submission Accepted
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Neurology Prescription Sales Tracker -- Week Ending 7/24/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Injunction Denied For BIIB in Tecfidera Appeal Proceeding
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department